Prosecution Insights
Last updated: November 04, 2026
Application No. 18/666,134

CAPILLARY NUTRITIONAL COMPLEX

Final Rejection §101§103
Filed
May 16, 2024
Priority
Jun 07, 2023 — ES U202331005
Examiner
SPAINE, ROBERT FRANKLIN
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Natural Folic S L
OA Round
2 (Final)
80%
Grant Probability
Favorable
3-4
OA Rounds
3m
Est. Remaining
80%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allowance Rate
8 granted / 10 resolved
+20.0% vs TC avg
Minimal +0% lift
Without
With
+0.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
56 currently pending
Career history
59
Total Applications
across all art units

Statute-Specific Performance

§101
14.4%
-25.6% vs TC avg
§103
36.6%
-3.4% vs TC avg
§102
8.3%
-31.7% vs TC avg
§112
29.2%
-10.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 10 resolved cases

Office Action

§101 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This office action is in response to the amendment received on August 3rd, 2026. Any objections or rejections not reiterated below are hereby withdrawn. Claim 1 is pending and was examined on the merits. Withdrawal of Objections and Rejections Applicant’s arguments, filed August 3rd, 2026, with respect to the objection to the specification have been fully considered and are persuasive. The applicant has amended the specification to correct the spelling of the term “Pygeum”. The objection to the specification has been withdrawn. Applicant’s arguments, filed August 3rd, 2026, with respect to the rejection of claim 1 under have been fully considered and are persuasive. On August 3rd, 2026, the applicant filed a terminal disclaimer for the instant application with respect to application # 18665934. This terminal disclaimer has been approved. The rejection of claim 1 under has been withdrawn. Pending Objections and Rejections Claim 1 is objected to because of the following informalities: the applicant has corrected the spelling of the term "Pygeum". Appropriate correction is suggested. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claim 1 is rejected under 35 U.S.C. 101 because the claimed invention is directed to a judicial exception (i.e., a law of nature, a natural phenomenon, or an abstract idea) without significantly more. Applicant's arguments filed August 3rd, 2026 have been fully considered but they are not persuasive. The compounds in the claimed compositions are in a composition having a physical form distinct from any of the naturally occurring sources. The applicant alleges “The compound physical properties compared to the raw natural are different, …”. However, the claims are drawn to a nutritional complex. Therefore, rather than analyzing the claimed product based on physical properties, the examiner analyzes the claimed product based on biological functions or activities; see MPEP 2106.04(c) II. B. “Appropriate characteristics can be expressed as the nature-based product’s structure, function, and/or other properties, and are evaluated on a case-by-case basis”. In their remarks, the applicant implies that the combination (understood as the claimed combination of ingredients) shows an unexpected result in comparison with a separate use, and that the “product of the present invention has been chemically treated to obtain the final combination, whereby the complex shows an unexpected synergistic effect”. However, the applicant has not cited support in the instant disclosure for a synergistic effect, and the examiner has not found support for a synergistic effect in the instant disclosure. The rejection of claim 1 under 35 U.S.C 101 is maintained. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claim 1 is rejected under 35 U.S.C. 103 as being unpatentable over Phillips (NZ 600777 A); and further in view of Li and Zhang (CN 107596049 A), abbreviated "Li"; Weston (US 20130101569 A1), Morley (US 10709659 B1); Uehara (JP 2002322050 A); Ishikawa et al. (JP 2012144440 A), abbreviated "Ishikawa"; Shmid (RU 2336890 C2); IVY GmbH (DE 202018101130 U1); and Hasebe (JP 2004189688 A). Applicant's arguments filed August 3rd, 2026 have been fully considered but they are not persuasive. The applicant recites the combination of ingredients of the nutritional complex and implies that this combination shows . The examiner thanks the applicant for clearly and concisely presenting their position. However, it is noted that the feature upon which applicant relies (i.e., an unexpected synergistic effect in comparison with the effect of each compound by itself according to its properties) is not recited in the rejected claim, the applicant has not pointed out where this feature is supported in the instant disclosure, and the examiner has not found support for this feature in the instant disclosure. The rejection of claim 1 under 35 U.S.C. 103 is maintained. Conclusion No claims are allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert F Spaine whose telephone number is (571)272-9099. The examiner can normally be reached 8:00 AM - 4:00 PM United States Eastern Time, Monday-Friday. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand Desai can be reached at (571) 272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /R.F.S./Examiner, Art Unit 1655 /ANAND U DESAI/Supervisory Patent Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

May 16, 2024
Application Filed
May 05, 2026
Non-Final Rejection mailed — §101, §103
Aug 03, 2026
Response Filed
Oct 09, 2026
Final Rejection mailed — §101, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773438
METHOD OF EXTRACTION OF PROANTHOCYANIDINS COMPOUND FROM PINE BARK OF PINUS ROXBURGHII
2y 11m to grant Granted Oct 27, 2026
Patent 12751986
COMPOSITION FOR INHIBITING PROLIFERATION OF TUMOR COMPRISING RUBUS COREANUS EXTRACT AS EFFECTIVE COMPONENT
2y 10m to grant Granted Oct 06, 2026
Patent 12728144
Composition Based on Natural Ingredients and Use of the Composition for Improving Mental Health
4y 2m to grant Granted Sep 08, 2026
Study what changed to get past this examiner. Based on 3 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
80%
Grant Probability
80%
With Interview (+0.0%)
2y 9m (~3m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 10 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month